SANTA CLARA, Calif. — November 21, 2008 — OmniVision Technologies, Inc. (Nasdaq: OVTI), a leading independent supplier of CMOS image sensors, today introduced the OV6930, the latest addition to its portfolio of medical image sensors. The new low power OV6930 is a 400 by 400 pixel square graphics array, or SquareGA™, CMOS image sensor with an optical format of 1/10 inch and a packaged footprint of 1.8 mm x 1.8 mm, making it ideal for camera applications that require less than 2.8 mm outside diameter, such as medical endoscopes for minimally invasive medical procedures.
The OV6930 uses a three micron OmniPixel®3-HS pixel, which enables it to achieve best-in-class low light performance of 3300 mV/Lux-second. Currently, no other CMOS image sensor on the market offers the same high performance and sensitivity in such a small form factor, making the OV6930 a very compelling solution for the medical device market.
“OmniVision’s first generation medical sensor (OV6920) has been successfully adopted by multiple customers that have been approved by the FDA or other regulatory agencies worldwide,” said Grahame Cooney, Product Marketing Director at OmniVision. “With the OV6930, OmniVision is able to further leverage its success in the medical imaging market. The sensor’s size and performance enable an even broader scope of medical endoscopy applications including colonoscopy, gastroscopy, OB/GYN, urology and bronchoscopy.”
The OV6930 provides full-frame or cropped analog images in RAW RGB format via the control of a new, patent pending serial I/O, which allows for two-wire cabling up to 14 feet and contributes to its very low power consumption of 80mW with and 10mW without IO usage. It has an image array capable of operating at 30 frames per second (fps) in full 400 x 400 resolution, and 60 fps at 400 x 200 resolution with simplified exposure control, which is programmable through the serial interface. The OV6930 uses proprietary sensor technology to improve image quality by reducing or eliminating common lighting or electrical sources of image contamination, such as fixed pattern noise and smearing, to produce a clean, fully stable color image.
For additional information on OmniVision’s medical imaging products, please visit www.ovt.com.
Certain statements in this press release, including statements regarding the expected benefits, performance and capabilities of the OV6930 CMOS image sensors are forward-looking statements that are subject to risks and uncertainties. These risks and uncertainties, which could cause the forward-looking statements and OmniVision’s results to differ materially, include, without limitation: potential errors, design flaws or other problems with the OV6930; customer acceptance, demand, and other risks detailed from time to time in OmniVision’s Securities and Exchange Commission filings and reports, including, but not limited to, OmniVision’s annual report filed on Form 10-K and quarterly reports filed on Form 10-Q. OmniVision expressly disclaims any obligation to update information contained in any forward-looking statement.